AI Science Tracker

CycleRFdiffusion-designed TP4 is a reproducible cyclic peptide binder to TREM2

Weill Cornell Medicine; Macao Polytechnic University; University of Gdańsk · 21 Dec 2025 · biology

Discovery

CycleRFdiffusion-designed TP4 is a reproducible cyclic peptide binder to TREM2

A structure-conditioned workflow combining CycleRFdiffusion, ProteinMPNN and HighFold generated and screened 1,500 cyclic peptide–TREM2 complexes and prioritized four candidates. The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays. The authors report favorable plasma stability and moderate metabolic stability, presenting the work as an initial proof of concept for TREM2-targeted cyclic binders.

Technology: CycleRFdiffusion backbone design, ProteinMPNN sequence design and HighFold structural prediction/screening

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays.
  • Still unknown: The only reported lead, TP4, is described as a weak binder. The evidence is biophysical binding and stability profiling, not demonstrated modulation of TREM2 signaling, microglial function, disease pathology or therapeutic efficacy. Treat this as proof-of-concept binder discovery.
  • AI role: The AI pipeline generated and ranked 1,500 candidate cyclic peptide–TREM2 complexes based on structure, sequence and predicted energetics, from which four were selected for experiments; TP4 was then assessed with multiple orthogonal binding assays.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41435973/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.